Autolus Therapeutics (NASDAQ:AUTL) Upgraded to “Sell” at Wall Street Zen

Wall Street Zen upgraded shares of Autolus Therapeutics (NASDAQ:AUTL) from a strong sell rating to a sell rating in a research note published on Saturday.

Other analysts have also recently issued research reports about the stock. Weiss Ratings cut shares of Autolus Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Friday, July 31st. Jefferies Financial Group raised Autolus Therapeutics to a “strong-buy” rating in a research report on Monday, April 20th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $10.00 target price on shares of Autolus Therapeutics in a report on Monday, August 3rd. Two investment analysts have rated the stock with a Strong Buy rating, five have issued a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, Autolus Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus target price of $8.75.

Autolus Therapeutics Price Performance

NASDAQ:AUTL opened at $2.11 on Friday. Autolus Therapeutics has a one year low of $1.17 and a one year high of $2.52. The company has a market cap of $561.59 million, a PE ratio of -1.94 and a beta of 2.07. The firm’s 50 day simple moving average is $1.59 and its 200 day simple moving average is $1.54.

Autolus Therapeutics (NASDAQ:AUTL) last announced its quarterly earnings results on Friday, May 15th. The company reported ($0.27) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.29) by $0.02. The firm had revenue of $26.22 million during the quarter, compared to analysts’ expectations of $26.27 million. Autolus Therapeutics had a negative net margin of 311.98% and a negative return on equity of 128.59%. Equities research analysts expect that Autolus Therapeutics will post -0.86 EPS for the current year.

Institutional Investors Weigh In On Autolus Therapeutics

Institutional investors have recently modified their holdings of the company. Alphabet Inc. bought a new position in Autolus Therapeutics during the second quarter worth $1,117,000. Syncona Portfolio Ltd bought a new stake in Autolus Therapeutics during the second quarter valued at $26,625,152,000. Hennion & Walsh Asset Management Inc. boosted its position in Autolus Therapeutics by 2.5% during the second quarter. Hennion & Walsh Asset Management Inc. now owns 451,403 shares of the company’s stock valued at $722,000 after acquiring an additional 11,197 shares during the last quarter. GAMMA Investing LLC grew its holdings in Autolus Therapeutics by 115.6% during the 2nd quarter. GAMMA Investing LLC now owns 15,499 shares of the company’s stock worth $25,000 after acquiring an additional 8,309 shares during the period. Finally, Waverly Advisors LLC acquired a new stake in Autolus Therapeutics during the 1st quarter worth about $37,000. 72.83% of the stock is owned by institutional investors.

About Autolus Therapeutics

Autolus Therapeutics is a clinical-stage biopharmaceutical company specializing in the development of next-generation, programmed T cell therapies for the treatment of cancer. The company leverages proprietary technologies to engineer autologous T cells that target and eradicate tumor cells, with the aim of improving safety, efficacy and durability over existing cell therapies. Its R&D platform integrates antigen receptor design, gene editing and manufacturing optimization to generate candidates tailored for specific hematologic malignancies and solid tumor indications.

The company’s leading pipeline candidates include AUTO1, an optimized CD19-targeted CAR-T therapy for relapsed or refractory acute lymphoblastic leukemia, and AUTO3, a dual-targeted CD19/22 CAR-T program in development for diffuse large B-cell lymphoma.